Final Six-Month Spending Bill Likely to Neglect Generic, Biosimilar Fees

Drug Industry Daily
The Senate is unlikely to alter a House-approved continuing resolution that will keep the FDA and federal government open through March 27, leaving the agency without permission to collect the newly created generic and biosimilar user fees.

To View This Article:


Subscribe To Drug Industry Daily